Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Depreciation & Amortization (CF) (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Depreciation & Amortization (CF) data on record, last reported at $100000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 50.0% year-over-year to $100000.0; the TTM value through Dec 2025 reached $500000.0, down 44.44%, while the annual FY2025 figure was $500000.0, 44.44% down from the prior year.
  • Depreciation & Amortization (CF) reached $100000.0 in Q4 2025 per AMLX's latest filing, roughly flat from $100000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $302000.0 in Q3 2023 and bottomed at $10000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $151350.0, with a median of $173500.0 recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): surged 1550.0% in 2022, then plummeted 50.0% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $22000.0 in 2021, then surged by 727.27% to $182000.0 in 2022, then surged by 65.38% to $301000.0 in 2023, then tumbled by 33.55% to $200000.0 in 2024, then tumbled by 50.0% to $100000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $100000.0 in Q4 2025, $100000.0 in Q3 2025, and $100000.0 in Q2 2025.